MWNA
DAWN

Marshall Wace North America’s Day One Biopharmaceuticals DAWN Stock Holding History

Marshall Wace North America’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-41,147
Closed -$937K – 1484
2021
Q2 		$937K Buy
+41,147
New +$858K ﹤0.01% 1033

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Marshall Wace North America's DAWN Position: Q3 2021 in Review

Marshall Wace North America sold out of Day One Biopharmaceuticals (DAWN) in Q3 2021, closing a stake of 41,147 shares — an estimated $937K sold.

Marshall Wace North America first reported a position in DAWN in Q2 2021 and held it in 1 quarter. The position peaked at $937K in Q2 2021. 45 funds tracked by Wall St. Rank hold DAWN as of Q3 2021.

  • Marshall Wace North America reported no remaining Day One Biopharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 41,147 Day One Biopharmaceuticals shares in Q3 2021, an estimated $937K.
  • Marshall Wace North America first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Marshall Wace North America's Day One Biopharmaceuticals position peaked at $937K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.